Menu
Kissy is an attorney with more than 20 years of experience, specializing in litigation, business development, and corporate representation. Most recently she served as Associate General Counsel at CryoLife, Inc., and General Counsel of its subsidiary, On-X Life Technologies, Inc., where she supported the Board of Directors and served as lead counsel to its European and Asian business units. She previously founded a cause lawyering firm committed to challenging the Georgia constitutional amendment barring same-sex marriage, litigated at Williams & Connolly LLP in Washington, D.C., and clerked for the Honorable Thomas Penfield Jackson on the Federal District Court for the District of Columbia. Kissy holds a JD from Harvard Law School and a BA from Yale College.
Kissy is an attorney with more than 20 years of experience, specializing in litigation, business development, and corporate representation. Most recently she served as Associate General Counsel at CryoLife, Inc., and General Counsel of its subsidiary, On-X Life Technologies, Inc., where she supported the Board of Directors and served as lead counsel to its European and Asian business units. She previously founded a cause lawyering firm committed to challenging the Georgia constitutional amendment barring same-sex marriage, litigated at Williams & Connolly LLP in Washington, D.C., and clerked for the Honorable Thomas Penfield Jackson on the Federal District Court for the District of Columbia. Kissy holds a JD from Harvard Law School and a BA from Yale College.
Kissy is an attorney with more than 20 years of experience, specializing in litigation, business development, and corporate representation. Most recently she served as Associate General Counsel at CryoLife, Inc., and General Counsel of its subsidiary, On-X Life Technologies, Inc., where she supported the Board of Directors and served as lead counsel to its European and Asian business units. She previously founded a cause lawyering firm committed to challenging the Georgia constitutional amendment barring same-sex marriage, litigated at Williams & Connolly LLP in Washington, D.C., and clerked for the Honorable Thomas Penfield Jackson on the Federal District Court for the District of Columbia. Kissy holds a JD from Harvard Law School and a BA from Yale College.
Jodi is a highly accomplished, results-driven CFO and management executive with more than 30 years of progressive experience in finance and operation management within publicly traded, start-ups, and global organizations. She has demonstrated ability to lead strategic transformation that drives growth, streamlines operations, and increases efficiency and bottom-line profit. Strong qualifications in change management and productivity improvement in addition to developing and implementing financial controls and processes. Jodi possesses solid leadership, communication, and interpersonal skills to establish rapport with all levels of staff and management.
Jodi is a highly accomplished, results-driven CFO and management executive with more than 30 years of progressive experience in finance and operation management within publicly traded, start-ups, and global organizations. She has demonstrated ability to lead strategic transformation that drives growth, streamlines operations, and increases efficiency and bottom-line profit. Strong qualifications in change management and productivity improvement in addition to developing and implementing financial controls and processes. Jodi possesses solid leadership, communication, and interpersonal skills to establish rapport with all levels of staff and management.
Jodi is a highly accomplished, results-driven CFO and management executive with more than 30 years of progressive experience in finance and operation management within publicly traded, start-ups, and global organizations. She has demonstrated ability to lead strategic transformation that drives growth, streamlines operations, and increases efficiency and bottom-line profit. Strong qualifications in change management and productivity improvement in addition to developing and implementing financial controls and processes. Jodi possesses solid leadership, communication, and interpersonal skills to establish rapport with all levels of staff and management.
Kissy is an attorney with more than 20 years of experience, specializing in litigation, business development, and corporate representation. Most recently she served as Associate General Counsel at CryoLife, Inc., and General Counsel of its subsidiary, On-X Life Technologies, Inc., where she supported the Board of Directors and served as lead counsel to its European and Asian business units. She previously founded a cause lawyering firm committed to challenging the Georgia constitutional amendment barring same-sex marriage, litigated at Williams & Connolly LLP in Washington, D.C., and clerked for the Honorable Thomas Penfield Jackson on the Federal District Court for the District of Columbia. Kissy holds a JD from Harvard Law School and a BA from Yale College.
Jodi is a highly accomplished, results-driven CFO and management executive with more than 30 years of progressive experience in finance and operation management within publicly traded, start-ups, and global organizations. She has demonstrated ability to lead strategic transformation that drives growth, streamlines operations, and increases efficiency and bottom-line profit. Strong qualifications in change management and productivity improvement in addition to developing and implementing financial controls and processes. Jodi possesses solid leadership, communication, and interpersonal skills to establish rapport with all levels of staff and management.
Chad leads TwinStrand’s board. He has more than 28 years’ of experience investing in IT and life sciences and serves on the boards of multiple other companies, including NanoString. Chad is the Managing Director of OVP Venture Partners, which has invested in 130 companies, with 53 exits, including 23 IPOs. Notable successes include WatchGuard, Seattle Genetics, and Rosetta Inpharmatics. Prior to joining OVP in 1987, Chad worked in the cardiovascular medical device division of Cobe Laboratories and as a General Partner at H&Q Venture Partners where he invested in IT and life sciences.
Chad leads TwinStrand’s board. He has more than 28 years’ of experience investing in IT and life sciences and serves on the boards of multiple other companies, including NanoString. Chad is the Managing Director of OVP Venture Partners, which has invested in 130 companies, with 53 exits, including 23 IPOs. Notable successes include WatchGuard, Seattle Genetics, and Rosetta Inpharmatics. Prior to joining OVP in 1987, Chad worked in the cardiovascular medical device division of Cobe Laboratories and as a General Partner at H&Q Venture Partners where he invested in IT and life sciences.
Soma is a Managing Director at Madrona Venture Group focusing on B2B and enterprise related start-ups. Soma invests across a wide variety of technology areas including machine learning / artificial intelligence, intelligent applications, next-generation cloud infrastructure, multi-sense user interfaces and robotic process automation. More recently, Soma has also been investing in companies at the intersection of life science and computer science where there is high potential for using data, ML and AI to accelerate innovation in this space. Prior to joining Madrona in 2015, Soma had a successful twenty-seven year long career with Microsoft where he most recently was Corporate Vice President of the Developer Division. Soma has long been an angel investor in a wide range of technology start-ups both in the U.S. and internationally.
Soma is a Managing Director at Madrona Venture Group focusing on B2B and enterprise related start-ups. Soma invests across a wide variety of technology areas including machine learning / artificial intelligence, intelligent applications, next-generation cloud infrastructure, multi-sense user interfaces and robotic process automation. More recently, Soma has also been investing in companies at the intersection of life science and computer science where there is high potential for using data, ML and AI to accelerate innovation in this space. Prior to joining Madrona in 2015, Soma had a successful twenty-seven year long career with Microsoft where he most recently was Corporate Vice President of the Developer Division. Soma has long been an angel investor in a wide range of technology start-ups both in the U.S. and internationally.
Chad leads TwinStrand’s board. He has more than 28 years’ of experience investing in IT and life sciences and serves on the boards of multiple other companies, including NanoString. Chad is the Managing Director of OVP Venture Partners, which has invested in 130 companies, with 53 exits, including 23 IPOs. Notable successes include WatchGuard, Seattle Genetics, and Rosetta Inpharmatics. Prior to joining OVP in 1987, Chad worked in the cardiovascular medical device division of Cobe Laboratories and as a General Partner at H&Q Venture Partners where he invested in IT and life sciences.
Soma is a Managing Director at Madrona Venture Group focusing on B2B and enterprise related start-ups. Soma invests across a wide variety of technology areas including machine learning / artificial intelligence, intelligent applications, next-generation cloud infrastructure, multi-sense user interfaces and robotic process automation. More recently, Soma has also been investing in companies at the intersection of life science and computer science where there is high potential for using data, ML and AI to accelerate innovation in this space. Prior to joining Madrona in 2015, Soma had a successful twenty-seven year long career with Microsoft where he most recently was Corporate Vice President of the Developer Division. Soma has long been an angel investor in a wide range of technology start-ups both in the U.S. and internationally.
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Prior to joining Section 32 in 2017, he served as CEO and then Chairman of Foundation Medicine. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010. He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Mike brings a breadth of understanding in personalized medicine with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University, as well as the Advisory Board for Mission Hospital’s Leonard Cancer Institute.
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Prior to joining Section 32 in 2017, he served as CEO and then Chairman of Foundation Medicine. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010. He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Mike brings a breadth of understanding in personalized medicine with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University, as well as the Advisory Board for Mission Hospital’s Leonard Cancer Institute.
Jason has spent his entire career focused on innovations that remove disparity and allow mass adoption of cutting-edge products. At Stanford University School of Medicine, on the heels of the draft of the human genome, he developed several novel functional genomics technologies that were licensed into products. Jason was an early employee at Ion Torrent in 2008 and helped build the first scalable electronic bench-top DNA sequencer ultimately facilitating democratization of genomics. After Ion was acquired by Life Technologies, Jason co-founded ArcherDx and BabyGenes in 2013. Archer merged into Invitae in 2020 to improve access to centralized and decentralized molecular diagnostics across the cancer patient continuum. Over the last 2 years Jason has been exploring electronic biosensors and their capability to offer rapid and inexpensive molecular diagnostics, first as the CEO of Genapsys, and now Sequencing Health. Jason was a board director at Archer, BabyGenes, Invitae, Genapsys, and IsoPlexis. He is currently a director at Sequencing Health and an Independent Director at InterVenn and TwinStrand Biosciences.
Jason has spent his entire career focused on innovations that remove disparity and allow mass adoption of cutting-edge products. At Stanford University School of Medicine, on the heels of the draft of the human genome, he developed several novel functional genomics technologies that were licensed into products. Jason was an early employee at Ion Torrent in 2008 and helped build the first scalable electronic bench-top DNA sequencer ultimately facilitating democratization of genomics. After Ion was acquired by Life Technologies, Jason co-founded ArcherDx and BabyGenes in 2013. Archer merged into Invitae in 2020 to improve access to centralized and decentralized molecular diagnostics across the cancer patient continuum. Over the last 2 years Jason has been exploring electronic biosensors and their capability to offer rapid and inexpensive molecular diagnostics, first as the CEO of Genapsys, and now Sequencing Health. Jason was a board director at Archer, BabyGenes, Invitae, Genapsys, and IsoPlexis. He is currently a director at Sequencing Health and an Independent Director at InterVenn and TwinStrand Biosciences.
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Prior to joining Section 32 in 2017, he served as CEO and then Chairman of Foundation Medicine. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010. He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Mike brings a breadth of understanding in personalized medicine with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University, as well as the Advisory Board for Mission Hospital’s Leonard Cancer Institute.
Jason has spent his entire career focused on innovations that remove disparity and allow mass adoption of cutting-edge products. At Stanford University School of Medicine, on the heels of the draft of the human genome, he developed several novel functional genomics technologies that were licensed into products. Jason was an early employee at Ion Torrent in 2008 and helped build the first scalable electronic bench-top DNA sequencer ultimately facilitating democratization of genomics. After Ion was acquired by Life Technologies, Jason co-founded ArcherDx and BabyGenes in 2013. Archer merged into Invitae in 2020 to improve access to centralized and decentralized molecular diagnostics across the cancer patient continuum. Over the last 2 years Jason has been exploring electronic biosensors and their capability to offer rapid and inexpensive molecular diagnostics, first as the CEO of Genapsys, and now Sequencing Health. Jason was a board director at Archer, BabyGenes, Invitae, Genapsys, and IsoPlexis. He is currently a director at Sequencing Health and an Independent Director at InterVenn and TwinStrand Biosciences.
Chad leads TwinStrand’s board. He has more than 28 years’ of experience investing in IT and life sciences and serves on the boards of multiple other companies, including NanoString. Chad is the Managing Director of OVP Venture Partners, which has invested in 130 companies, with 53 exits, including 23 IPOs. Notable successes include WatchGuard, Seattle Genetics, and Rosetta Inpharmatics. Prior to joining OVP in 1987, Chad worked in the cardiovascular medical device division of Cobe Laboratories and as a General Partner at H&Q Venture Partners where he invested in IT and life sciences.
Soma is a Managing Director at Madrona Venture Group focusing on B2B and enterprise related start-ups. Soma invests across a wide variety of technology areas including machine learning / artificial intelligence, intelligent applications, next-generation cloud infrastructure, multi-sense user interfaces and robotic process automation. More recently, Soma has also been investing in companies at the intersection of life science and computer science where there is high potential for using data, ML and AI to accelerate innovation in this space. Prior to joining Madrona in 2015, Soma had a successful twenty-seven year long career with Microsoft where he most recently was Corporate Vice President of the Developer Division. Soma has long been an angel investor in a wide range of technology start-ups both in the U.S. and internationally.
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences. Prior to joining Section 32 in 2017, he served as CEO and then Chairman of Foundation Medicine. Previously, he was President and COO of Clarient, a national leader in molecular pathology, which was acquired by GE Healthcare in 2010. He currently serves as a member of the Board of Directors for Tango Therapeutics, Nusano, Vineti, Singular Genomics, Adaptive Biotechnologies, Octave Health, Sema4, Cradle Genomics, the Personalized Medicine Coalition, the GO2 Foundation, and the Mission Hospital Foundation (Providence/St. Joseph Health). Mike brings a breadth of understanding in personalized medicine with a particular interest and focus on defeating cancer. He is also a member of the President’s Leadership Council at Thomas Jefferson University, as well as the Advisory Board for Mission Hospital’s Leonard Cancer Institute.
Jason has spent his entire career focused on innovations that remove disparity and allow mass adoption of cutting-edge products. At Stanford University School of Medicine, on the heels of the draft of the human genome, he developed several novel functional genomics technologies that were licensed into products. Jason was an early employee at Ion Torrent in 2008 and helped build the first scalable electronic bench-top DNA sequencer ultimately facilitating democratization of genomics. After Ion was acquired by Life Technologies, Jason co-founded ArcherDx and BabyGenes in 2013. Archer merged into Invitae in 2020 to improve access to centralized and decentralized molecular diagnostics across the cancer patient continuum. Over the last 2 years Jason has been exploring electronic biosensors and their capability to offer rapid and inexpensive molecular diagnostics, first as the CEO of Genapsys, and now Sequencing Health. Jason was a board director at Archer, BabyGenes, Invitae, Genapsys, and IsoPlexis. He is currently a director at Sequencing Health and an Independent Director at InterVenn and TwinStrand Biosciences.
David is a Partner at Soleus Capital where he focuses on private and public therapeutic and next-generation diagnostic companies. David has served on the board or as an observer for a number of companies including Antios Therapeutics and Parse Biosciences. Prior to joining Soleus in 2018, David completed his PhD at MIT in Immunology and Oncology after finishing his undergraduate studies at Princeton University.
David is a Partner at Soleus Capital where he focuses on private and public therapeutic and next-generation diagnostic companies. David has served on the board or as an observer for a number of companies including Antios Therapeutics and Parse Biosciences. Prior to joining Soleus in 2018, David completed his PhD at MIT in Immunology and Oncology after finishing his undergraduate studies at Princeton University.
David is a Partner at Soleus Capital where he focuses on private and public therapeutic and next-generation diagnostic companies. David has served on the board or as an observer for a number of companies including Antios Therapeutics and Parse Biosciences. Prior to joining Soleus in 2018, David completed his PhD at MIT in Immunology and Oncology after finishing his undergraduate studies at Princeton University.
Ronnie has over 35 years of experience in the Global Clinical and Molecular Diagnostics industry. Ronnie is currently the Managing Partner at pH Blueprint, an advisory firm that helps drive portfolio management, commercial go-to-market plans, organizational development, executive mentorship, product strategy, regulatory and reimbursement strategies for companies in the Biotech Tools and Molecular Diagnostics market.
Prior to joining pH Blueprint, Ronnie has served in several senior executive and C Suite roles such as CEO of Oncocyte, a Molecular Dx company located in Irvine CA. Previous leadership roles include President of the Genetic Sciences Division at Thermo Fisher Scientific following a merger with Life Technologies, where he served as President of the Medical Sciences Venture. During the merger, he oversaw the integration of Ion Torrent with the traditional genetic platform and content initiatives within Life Technologies to form a $2 billion division. Ronnie also served as Chief Executive Officer and Vice Chairman at Clarient Inc. from 2004 until 2010 when Clarient was purchased by GE Healthcare. At the close of the transaction, Ronnie oversaw the transition into GE Healthcare and established a strategic plan to expand GE’s presence in oncology. Ronnie currently serves as The Executive Chairman of SymBioSys, a cancer AI company, as well as serving on the Board of Directors of ASCO’s CancerlinQ, Quotient Dx, CellMax, and Precipio.
David is a Partner at Soleus Capital where he focuses on private and public therapeutic and next-generation diagnostic companies. David has served on the board or as an observer for a number of companies including Antios Therapeutics and Parse Biosciences. Prior to joining Soleus in 2018, David completed his PhD at MIT in Immunology and Oncology after finishing his undergraduate studies at Princeton University.
Larry’s research for more than 60 years has focused on human cancer. He is a scientific visionary, best known for the concept of a mutator phenotype in cancer, which is the principle that tumors form and evolve resistance to therapy by virtue of their tendency to acquire mutations at an accelerated rate. He has published extensively in the fields of molecular biology, biochemistry, fidelity of DNA replication, creation of artificial enzymes, and Duplex Sequencing. Dr. Loeb graduated from The City College of New York, received an MD degree from New York University, a Post-Doctoral fellowship at NIH, and a PhD from The University of California Berkeley. He is a professor in the Departments of Pathology and Biochemistry at the University of Washington where he served as director of the MD/PHD program for 23 years. He is past president of The American Association of Cancer Research, The Environmental Mutagen Society and a fellow of American Academy of Arts and Sciences.
Larry’s research for more than 60 years has focused on human cancer. He is a scientific visionary, best known for the concept of a mutator phenotype in cancer, which is the principle that tumors form and evolve resistance to therapy by virtue of their tendency to acquire mutations at an accelerated rate. He has published extensively in the fields of molecular biology, biochemistry, fidelity of DNA replication, creation of artificial enzymes, and Duplex Sequencing. Dr. Loeb graduated from The City College of New York, received an MD degree from New York University, a Post-Doctoral fellowship at NIH, and a PhD from The University of California Berkeley. He is a professor in the Departments of Pathology and Biochemistry at the University of Washington where he served as director of the MD/PHD program for 23 years. He is past president of The American Association of Cancer Research, The Environmental Mutagen Society and a fellow of American Academy of Arts and Sciences.
Jerry is a Member of the Clinical Research Division, Director of the Molecular Oncology CLIA Lab and the Kurt Enslein Endowed Chair at the Fred Hutchinson Cancer Research Center. He is a Professor of Medicine in the Division of Medical Oncology at the University of Washington. Dr. Radich’s research laboratory focuses on the molecular biology of response, resistance, and progression in acute and chronic myeloid leukemia. His clinical Molecular Oncology Lab provides the molecular diagnostic support for many institutional, US Intergroup, international, and pharmaceutical trials. Some of his major scientific contributions over the past three decades include being among the first to document the prevalence and significance of mutations in the Ras/MAPK signaling pathway in acute myeloid leukemia and recognition of the importance of measurable residual disease in ALL, AML and CML. He was awarded the International CML Foundation Award in 2017 and the Washington Global Health Alliance Partnership Award in 2019 for his lab’s work on diagnosing and monitoring chronic myeloid leukemia (CML) in the developing world. A mere subset of his many past and present leadership roles include: Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group, Inaugural Chair of the National Cancer Institute and National Institute of Health Leukemia Steering Committee, past member of the Board of Scientific Counselors of the NIH Genome Research Institute, past-chair of the CML Committee of the National Comprehensive Cancer Network and current member of the European Leukemia Network CML committee. He serves on the Scientific Board of the International CML Foundation and the Max Foundation and leads the Laboratory Committee of the NCI AML Precision Medicine Initiative and the Foundation of the NIH’s program in measurable residual disease in AML. Dr. Radich holds a BS with Honors in Biology from UC San Diego, an MS in Epidemiology from Harvard University School of Public Health, and an MD from UC Davis School of Medicine.
Jerry is a Member of the Clinical Research Division, Director of the Molecular Oncology CLIA Lab and the Kurt Enslein Endowed Chair at the Fred Hutchinson Cancer Research Center. He is a Professor of Medicine in the Division of Medical Oncology at the University of Washington. Dr. Radich’s research laboratory focuses on the molecular biology of response, resistance, and progression in acute and chronic myeloid leukemia. His clinical Molecular Oncology Lab provides the molecular diagnostic support for many institutional, US Intergroup, international, and pharmaceutical trials. Some of his major scientific contributions over the past three decades include being among the first to document the prevalence and significance of mutations in the Ras/MAPK signaling pathway in acute myeloid leukemia and recognition of the importance of measurable residual disease in ALL, AML and CML. He was awarded the International CML Foundation Award in 2017 and the Washington Global Health Alliance Partnership Award in 2019 for his lab’s work on diagnosing and monitoring chronic myeloid leukemia (CML) in the developing world. A mere subset of his many past and present leadership roles include: Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group, Inaugural Chair of the National Cancer Institute and National Institute of Health Leukemia Steering Committee, past member of the Board of Scientific Counselors of the NIH Genome Research Institute, past-chair of the CML Committee of the National Comprehensive Cancer Network and current member of the European Leukemia Network CML committee. He serves on the Scientific Board of the International CML Foundation and the Max Foundation and leads the Laboratory Committee of the NCI AML Precision Medicine Initiative and the Foundation of the NIH’s program in measurable residual disease in AML. Dr. Radich holds a BS with Honors in Biology from UC San Diego, an MS in Epidemiology from Harvard University School of Public Health, and an MD from UC Davis School of Medicine.
Larry’s research for more than 60 years has focused on human cancer. He is a scientific visionary, best known for the concept of a mutator phenotype in cancer, which is the principle that tumors form and evolve resistance to therapy by virtue of their tendency to acquire mutations at an accelerated rate. He has published extensively in the fields of molecular biology, biochemistry, fidelity of DNA replication, creation of artificial enzymes, and Duplex Sequencing. Dr. Loeb graduated from The City College of New York, received an MD degree from New York University, a Post-Doctoral fellowship at NIH, and a PhD from The University of California Berkeley. He is a professor in the Departments of Pathology and Biochemistry at the University of Washington where he served as director of the MD/PHD program for 23 years. He is past president of The American Association of Cancer Research, The Environmental Mutagen Society and a fellow of American Academy of Arts and Sciences.
Jerry is a Member of the Clinical Research Division, Director of the Molecular Oncology CLIA Lab and the Kurt Enslein Endowed Chair at the Fred Hutchinson Cancer Research Center. He is a Professor of Medicine in the Division of Medical Oncology at the University of Washington. Dr. Radich’s research laboratory focuses on the molecular biology of response, resistance, and progression in acute and chronic myeloid leukemia. His clinical Molecular Oncology Lab provides the molecular diagnostic support for many institutional, US Intergroup, international, and pharmaceutical trials. Some of his major scientific contributions over the past three decades include being among the first to document the prevalence and significance of mutations in the Ras/MAPK signaling pathway in acute myeloid leukemia and recognition of the importance of measurable residual disease in ALL, AML and CML. He was awarded the International CML Foundation Award in 2017 and the Washington Global Health Alliance Partnership Award in 2019 for his lab’s work on diagnosing and monitoring chronic myeloid leukemia (CML) in the developing world. A mere subset of his many past and present leadership roles include: Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group, Inaugural Chair of the National Cancer Institute and National Institute of Health Leukemia Steering Committee, past member of the Board of Scientific Counselors of the NIH Genome Research Institute, past-chair of the CML Committee of the National Comprehensive Cancer Network and current member of the European Leukemia Network CML committee. He serves on the Scientific Board of the International CML Foundation and the Max Foundation and leads the Laboratory Committee of the NCI AML Precision Medicine Initiative and the Foundation of the NIH’s program in measurable residual disease in AML. Dr. Radich holds a BS with Honors in Biology from UC San Diego, an MS in Epidemiology from Harvard University School of Public Health, and an MD from UC Davis School of Medicine.
Larry’s research for more than 60 years has focused on human cancer. He is a scientific visionary, best known for the concept of a mutator phenotype in cancer, which is the principle that tumors form and evolve resistance to therapy by virtue of their tendency to acquire mutations at an accelerated rate. He has published extensively in the fields of molecular biology, biochemistry, fidelity of DNA replication, creation of artificial enzymes, and Duplex Sequencing. Dr. Loeb graduated from The City College of New York, received an MD degree from New York University, a Post-Doctoral fellowship at NIH, and a PhD from The University of California Berkeley. He is a professor in the Departments of Pathology and Biochemistry at the University of Washington where he served as director of the MD/PHD program for 23 years. He is past president of The American Association of Cancer Research, The Environmental Mutagen Society and a fellow of American Academy of Arts and Sciences.
Jerry is a Member of the Clinical Research Division, Director of the Molecular Oncology CLIA Lab and the Kurt Enslein Endowed Chair at the Fred Hutchinson Cancer Research Center. He is a Professor of Medicine in the Division of Medical Oncology at the University of Washington. Dr. Radich’s research laboratory focuses on the molecular biology of response, resistance, and progression in acute and chronic myeloid leukemia. His clinical Molecular Oncology Lab provides the molecular diagnostic support for many institutional, US Intergroup, international, and pharmaceutical trials. Some of his major scientific contributions over the past three decades include being among the first to document the prevalence and significance of mutations in the Ras/MAPK signaling pathway in acute myeloid leukemia and recognition of the importance of measurable residual disease in ALL, AML and CML. He was awarded the International CML Foundation Award in 2017 and the Washington Global Health Alliance Partnership Award in 2019 for his lab’s work on diagnosing and monitoring chronic myeloid leukemia (CML) in the developing world. A mere subset of his many past and present leadership roles include: Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group, Inaugural Chair of the National Cancer Institute and National Institute of Health Leukemia Steering Committee, past member of the Board of Scientific Counselors of the NIH Genome Research Institute, past-chair of the CML Committee of the National Comprehensive Cancer Network and current member of the European Leukemia Network CML committee. He serves on the Scientific Board of the International CML Foundation and the Max Foundation and leads the Laboratory Committee of the NCI AML Precision Medicine Initiative and the Foundation of the NIH’s program in measurable residual disease in AML. Dr. Radich holds a BS with Honors in Biology from UC San Diego, an MS in Epidemiology from Harvard University School of Public Health, and an MD from UC Davis School of Medicine.
For Research Use Only. Not for use in diagnostic procedures.
©2024 TwinStrand Biosciences, Inc. All rights reserved. All trademarks are the property of TwinStrand Biosciences, Inc. or their respective owners. Legal Notices
Stay up to date